Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 Shares

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 842 shares of Pro-Dex stock in a transaction that occurred on Friday, March 28th. The stock was sold at an average price of $50.00, for a total value of $42,100.00. Following the completion of the transaction, the director now owns 278,945 shares of the company's stock, valued at approximately $13,947,250. The trade was a 0.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Pro-Dex Price Performance

PDEX stock traded up $0.25 on Friday, hitting $50.90. 37,363 shares of the company's stock traded hands, compared to its average volume of 22,955. The stock has a market cap of $165.98 million, a price-to-earnings ratio of 25.32 and a beta of 0.40. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average of $41.10 and a 200-day moving average of $40.76. Pro-Dex, Inc. has a 1-year low of $16.84 and a 1-year high of $59.60.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, analysts forecast that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Pro-Dex

A number of large investors have recently made changes to their positions in the company. FMR LLC raised its stake in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock valued at $119,000 after purchasing an additional 1,028 shares during the period. Bank of New York Mellon Corp acquired a new position in Pro-Dex during the fourth quarter valued at $202,000. Trexquant Investment LP purchased a new stake in Pro-Dex in the 4th quarter worth about $252,000. Integrated Quantitative Investments LLC purchased a new position in Pro-Dex during the 4th quarter valued at about $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Pro-Dex in the fourth quarter worth approximately $255,000. Institutional investors and hedge funds own 15.28% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Pro-Dex from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.